Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials.

[1]  A. Hauschild,et al.  Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma , 2016 .

[2]  K. Flaherty,et al.  Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  C. Berking,et al.  Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab , 2016, Clinical Cancer Research.

[4]  D. Schadendorf,et al.  Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials. , 2015, The Lancet. Oncology.

[5]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[6]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[7]  C. Horak,et al.  Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. , 2015, JAMA oncology.

[8]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[9]  J. Wolchok,et al.  Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. , 2015 .

[10]  K. Flaherty,et al.  Updated overall survival (OS) results for BRF113220, a phase I-II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM). , 2015 .

[11]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[12]  A. Iafrate,et al.  Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies , 2015, Cancer Immunology Research.

[13]  K. Flaherty,et al.  Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  D. Schadendorf,et al.  Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.

[15]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[16]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[17]  L. Haydu,et al.  The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition , 2014, Cancer.

[18]  J. Wolchok,et al.  Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. , 2014 .

[19]  Z. Szallasi,et al.  Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma , 2014, Cancer Immunology, Immunotherapy.

[20]  C. Garbe,et al.  Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy , 2013, PloS one.

[21]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[22]  C. Ng,et al.  NRAS mutation status is an independent prognostic factor in metastatic melanoma , 2012, Cancer.

[23]  R. Sullivan,et al.  Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma , 2012, Journal of immunotherapy.

[24]  D. Schadendorf,et al.  Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma , 2011, Cancer.

[25]  G. Mann,et al.  Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[28]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[29]  T. Therneau,et al.  An Introduction to Recursive Partitioning Using the RPART Routines , 2015 .

[30]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[31]  D. Pregibon,et al.  Tree-based Models , 1992, Advanced Textbooks in Mathematics.

[32]  D. R. Cox,et al.  Analysis of Survival Data , 1984 .